

## Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health – Europe 35 (2023) 100747]

Evans, Rachael A.; Dube, Sabada; Lu, Yi; Yates, Mark; Arnetorp, Sofie; Barnes, Eleanor; Bell, Samira; Carty, Lucy; Evans, Kathryn; Graham, Sophie; Justo, Nahila; Moss, Paul; Venkatesan, Sudhir; Yokota, Renata; Ferreira, Catia; McNulty, Richard; Taylor, Sylvia; Quint, Jennifer K.

DOI:

[10.1016/j.lanepe.2024.101008](https://doi.org/10.1016/j.lanepe.2024.101008)

License:

Creative Commons: Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)

*Document Version*

Publisher's PDF, also known as Version of record

*Citation for published version (Harvard):*

Evans, RA, Dube, S, Lu, Y, Yates, M, Arnetorp, S, Barnes, E, Bell, S, Carty, L, Evans, K, Graham, S, Justo, N, Moss, P, Venkatesan, S, Yokota, R, Ferreira, C, McNulty, R, Taylor, S & Quint, JK 2024, 'Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health – Europe 35 (2023) 100747]', *The Lancet Regional Health - Europe*, vol. 44, 101008. <https://doi.org/10.1016/j.lanepe.2024.101008>

[Link to publication on Research at Birmingham portal](#)

### General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

### Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact [UBIRA@lists.bham.ac.uk](mailto:UBIRA@lists.bham.ac.uk) providing details and we will remove access to the work immediately and investigate.

Download date: 05. Nov. 2024

# Corrigendum to 'Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study' [The Lancet Regional Health – Europe 35 (2023) 100747]



Rachael A. Evans,<sup>a</sup> Sabada Dube,<sup>b</sup> Yi Lu,<sup>c</sup> Mark Yates,<sup>d</sup> Sofie Arnetorp,<sup>e</sup> Eleanor Barnes,<sup>f</sup> Samira Bell,<sup>g</sup> Lucy Carty,<sup>h</sup> Kathryn Evans,<sup>i</sup> Sophie Graham,<sup>c</sup> Nahila Justo,<sup>j</sup> Paul Moss,<sup>k,l</sup> Sudhir Venkatesan,<sup>m</sup> Renata Yokota,<sup>n</sup> Catia Ferreira,<sup>o</sup> Richard McNulty,<sup>p</sup> Sylvia Taylor,<sup>q</sup> and Jennifer K. Quint<sup>r,\*</sup>



<sup>a</sup>Department of Respiratory Sciences, University of Leicester, Leicester, United Kingdom

<sup>b</sup>AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom

<sup>c</sup>Evidera, The Ark, 201 Talgarth Road, London, W6 8BJ, United Kingdom

<sup>d</sup>Data Analytics - Real World Evidence, Evidera, London, United Kingdom

<sup>e</sup>Vaccines and Immune Therapies, Global Market Access and Pricing, AstraZeneca R&D, 431 83, Mölndal, Sweden

<sup>f</sup>Nuffield Department of Medicine, University of Oxford, OUH Hospital NHS Trust, Oxford, United Kingdom

<sup>g</sup>Population Health and Genomics, School of Medicine, University of Dundee, Ninewells Hospital, Dundee, DD1 9SY, Scotland, United Kingdom

<sup>h</sup>Medical and Payer Evidence Statistics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom

<sup>i</sup>Evidera, Waltham, MA 02451, United States

<sup>j</sup>Integrated Solutions – Real World Evidence, Evidera, Stockholm, Sweden

<sup>k</sup>Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom

<sup>l</sup>University Hospitals Birmingham, NHS Foundation Trust, Birmingham, United Kingdom

<sup>m</sup>Medical and Payer Evidence, BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom

<sup>n</sup>P95, Leuven, Belgium

<sup>o</sup>AstraZeneca LP, 1800 Concord Pike, Wilmington, DE, 19850-5437, USA

<sup>p</sup>Medical Affairs, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom

<sup>q</sup>Medical Evidence, AstraZeneca UK Limited, BioPharmaceuticals Medical, Vaccines & Immunotherapies, Eastbrook House, First Floor, Shaftesbury Road, Cambridge, CB2 8DU, United Kingdom

<sup>r</sup>National Heart & Lung Institute, Imperial College London, United Kingdom

The authors have noticed an error at the end of the Outcomes paragraph in the Methods section, where it currently reads 'COVID-19-related mortality, defined as a death in ONS mortality data with COVID-19 recorded as a cause of death, or an in-hospital death during a COVID-19 hospitalisation.' This should be replaced with 'COVID-19-related mortality, defined as a death in ONS mortality data with COVID-19 recorded as a cause of death.'

The Lancet Regional Health - Europe  
2024;44: 101008

Published Online xxx  
<https://doi.org/10.1016/j.lanepe.2024.101008>

DOI of original article: <https://doi.org/10.1016/j.lanepe.2023.100747>

\*Corresponding author.

E-mail address: [j.quint@imperial.ac.uk](mailto:j.quint@imperial.ac.uk) (J.K. Quint).

© 2024 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).